# Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

Study · id `cardio:ct-nct02561000` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02561000](<https://clinicaltrials.gov/study/NCT02561000>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02561000

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT02561000. Randomized; quadruple masking; primary purpose prevention. Start 2016-05-27 (actual); primary completion 2019-09-17 (actual). Results posted on 2021-03-09.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT02561000, source copy `cardio:ctgov-nct02561000-2025-04-16`, retrieved 2026-10-26)
- Started: 2016-05-27 (actual) (ClinicalTrials.gov record NCT02561000, source copy `cardio:ctgov-nct02561000-2025-04-16`, retrieved 2026-10-26)
- Primary completion: 2019-09-17 (actual) (ClinicalTrials.gov record NCT02561000, source copy `cardio:ctgov-nct02561000-2025-04-16`, retrieved 2026-10-26)
- Completion: 2019-09-17 (actual) (ClinicalTrials.gov record NCT02561000, source copy `cardio:ctgov-nct02561000-2025-04-16`, retrieved 2026-10-26)
- Results first posted: 2021-03-09 (ClinicalTrials.gov record NCT02561000, source copy `cardio:ctgov-nct02561000-2025-04-16`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02561000, source copy `cardio:ctgov-nct02561000-2025-04-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02561000-2025-04-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention
- Acronym: TRIP-PCI
- Condition: Arterial Occlusive Diseases
- Condition: Coronary Artery Disease
- Condition: Coronary Disease
- Condition: Arteriosclerosis
- Condition: Heart Diseases
- Condition: Myocardial Ischemia
- Condition: Vascular Diseases
- Condition: Acute Coronary Syndrome
- Intervention (Drug): PZ-128
- Intervention (Drug): Placebo
- Lead sponsor: Tufts Medical Center
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH
- Collaborator: RTI International
- Collaborator class: OTHER
- Collaborator: Inova Fairfax Hospital
- Collaborator class: OTHER
- Collaborator: University of Massachusetts, Worcester
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Tufts Medical Center (`cardio:org-tufts-medical-center`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)
- Registry lists this organization as a collaborator: University of Massachusetts, Worcester (`cardio:org-university-of-massachusetts-worcester`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study (`cardio:pubmed-33028101`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 8fd4fca47284f89ca29fcee6f115b3d7580a7fa9ff4abd36c4731d7818b0c38a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
